The hypoxia-inducible factor-1 (HIF-1) is a key regulator in the mammalian response to oxygen deficiency under both physiological and pathological conditions such as cancer. A number of studies indicated an association between tumor hypoxia, increased hypoxia-inducible factor (HIF-1alpha) levels and a poor prognosis. The HIF-1alpha regulation in response to hypoxia occurs primarily on the level of protein stability due to posttranslational hydroxylation. However, HIFalpha-subunits also respond to various growth factors, hormones, or cytokines under non-hypoxic conditions implicating the involvement of different kinase pathways in their regulation thereby increasing the interest in HIF-1alpha as a new drug target. Herein, we review current knowledge about phosphorylation-dependent HIF-1alpha regulation, HIF-1alpha protein-protein interactions and subcellular localization with emphasis on new therapeutic strategies targeting the HIF pathway.
No takes yet. Share an insight, caveat, or question.
Dimova et al. (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context:
More from Current Pharmaceutical Design